Physician profile
Michael Cronen
NPI 1609854520
$10,030.73
in general payments reported to CMS, 2019-2025
49 companies · $606 in 2025
The $606 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $916 · 2021: $2,527 · 2022: $2,316 · 2023: $1,369 · 2024: $763 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,865.31 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Si-Bone, INC. | $1,384.81 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,092.66 | 2019-2025 | Relistor |
| Biohaven Pharmaceuticals, INC. | $484.43 | 2021 | |
| Amgen INC. | $461.06 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $459.13 | 2019-2025 | Xtampza, Belbuca |
| Abbott Laboratories | $439.86 | 2021-2023 | Proclaim |
| Scilex Pharmaceuticals INC. | $343.86 | 2019-2024 | Ztlido |
| Lilly USA, LLC | $289.07 | 2019-2022 | |
| Daiichi Sankyo INC. | $269.11 | 2019 | |
| Currax Pharmaceuticals LLC | $246.36 | 2019-2024 | Onzetra Xsail, Contrave |
| Pfizer INC. | $245.40 | 2019-2023 | |
| Protega Pharmaceutials INC | $216.11 | 2022 | |
| Ibsa Pharma INC. | $214.91 | 2020-2025 | Tirosint, Licart, Tirosint |
| Hikma Pharmaceuticals USA | $197.41 | 2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cronen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.